<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345316</url>
  </required_header>
  <id_info>
    <org_study_id>FFI-1010-004</org_study_id>
    <nct_id>NCT03345316</nct_id>
  </id_info>
  <brief_title>Study of FFI-1010 in Pediatric Kidney Disease</brief_title>
  <official_title>Safety and Usability Evaluation Study of FFI-1010 Single Administration for Children Under 18 Years Old With Kidney Disease (Phase III Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuji Yakuhin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is revealing that the ratio of creatinine clearance (Ccr) to inulin
      clearance (Cin) measuring at the same time is more than 1.2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of Cin to Ccr measuring at the same time</measure>
    <time_frame>120 minutes</time_frame>
    <description>Demonstrating usability of inulin clearance by comparison between inulin clearance and creatinine clearance at the same time after the start of FFI-1010 administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Children Under 18 Years Old With Kidney Disease</condition>
  <arm_group>
    <arm_group_label>FFI-1010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFI-1010</intervention_name>
    <description>Intravenous single dosing</description>
    <arm_group_label>FFI-1010</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney disease patients requiring exact evaluation of kidney function

          -  eGFR: &gt;=30 and &lt;=89 mL/min/1.73m^2

        Exclusion Criteria:

          -  Edema on the day before start of study treatment

          -  Oliguria on the day before start of study treatment

          -  Dehydration on the day before start of study treatment

          -  Infection or inflammatory disease before administration

          -  History of epilepsy or organic brain disorder

          -  History of, clinically significant cardiac, hematologic, hepatic and pancreatic
             disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fuji Yakuhin Investigational sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

